Compare Amgen, Inc. (AMGN) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Genuine Parts Company — how do they compare? Amgen, Inc. trades at $356.5 (market cap $196.12B), while Genuine Parts Company trades at $126.32 (market cap $17.29B). The key difference: Amgen, Inc. is far larger — about 11.3× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| AMGN | GPC | |
|---|---|---|
Market Cap | $196.12B | $17.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $149.26 |
52-Week Low | $271.18 | $92.47 |
Enterprise Value | $241.41B | $23.50B |
Dividend Yield | 2.77% | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GPC trades at $125.62, up 1.09% with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $24.3B in 2025, though net margins compressed to 0.24%. Analyst consensus is mixed with 43% buy ratings and a $133 price target. Recent news highlights GPC's 70-year dividend growth streak and upcoming Q2 2026 earnings report on July 21, 2026.
GPC offers income stability with its Dividend King status but faces profitability challenges. The stock trades near analyst targets with moderate upside potential. Key risks include margin pressure from rising costs and competitive threats in auto parts distribution. Institutional sentiment remains cautiously optimistic given the stable dividend history amid earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
